阴道神经刺激和纤维肌痛:一个额外的治疗选择
Giulio Dolcini1, Martina Favretti1, Daniele Franculli2
1Department of Molecular Medicine, Sapienza University of Rome, Italy.
Clinical and experimental rheumatology
|June 27, 2025
概括
耳道神经调节疗法 (AVNTTM) 显著降低了纤维肌痛症状,改善了患者的睡眠质量. 这种治疗没有改变大脑衍生神经营养因子 (BDNF) 水平.
科学领域:
- 神经学 神经学
- 疼痛管理 疼痛管理
- 生物电子医学 生物电子医学
背景情况:
- 纤维肌痛 (FM) 是一种复杂的慢性疾病,病因不明,可能涉及自主神经系统功能障碍.
- 在FM的自主功能障碍可能会导致慢性疼痛,并改变神经炎症标志物,如脑衍生神经营养因子 (BDNF).
- 通过皮肤的迷走神经刺激 (tVNS) 增强了副交感活动,有望调节疼痛,情绪和睡眠.
研究的目的:
- 评估耳膜神经调节疗法 (AVNTTM) 在缓解纤维肌痛疾病严重性的有效性.
- 评估AVNTTM对纤维肌痛患者睡眠质量的影响.
- 为了研究AVNTTM治疗后血清BDNF水平的变化.
主要方法:
- 一项试点研究涉及18名被诊断患有纤维肌痛的患者.
- 患者接受了30分钟的AVNTTM会议,每周5次连续4周.
- 疾病严重程度,睡眠质量和血清BDNF水平在治疗前和后被评估.
主要成果:
- 在两周后 (p=0.03) 观察到WPI得分的显著降低,并在第4周 (p=0.004) 得到确认.
- 在第4周,经过修订的纤维肌痛影响问卷 (rFIQ) 总得分,一般健康状况和症状组件 (p≤0.02) 显著改善.
- 匹兹堡睡眠质量指数 (PSQI) 得分显著改善 (p=0.02),而BDNF水平没有显著变化.
结论:
- 在纤维肌痛患者中,AVNTTM显示出作为一种有效疗法的潜力,可以减少疾病的严重程度.
- 治疗显著改善了参与者的主观睡眠质量.
- 在研究期间,AVNTTM并没有导致血清BDNF水平发生显著变化.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
631
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
631
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
874
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
874
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K